dantrolene has been researched along with Arrhythmia in 28 studies
Dantrolene: Skeletal muscle relaxant that acts by interfering with excitation-contraction coupling in the muscle fiber. It is used in spasticity and other neuromuscular abnormalities. Although the mechanism of action is probably not central, dantrolene is usually grouped with the central muscle relaxants.
dantrolene : The hydrazone resulting from the formal condensation of 5-(4-nitrophenyl)furfural with 1-aminohydantoin. A ryanodine receptor antagonist used for the relief of chronic severe spasticity and malignant hyperthermia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ryanodine receptor 2 (RyR2) hyperactivity is observed in structural heart diseases that are a result of ischemia or heart failure." | 8.31 | Ryanodine receptor inhibition with acute dantrolene treatment reduces arrhythmia susceptibility in human hearts. ( Brennan-McLean, JA; Efimov, IR; Faye, NR; George, SA; Knollmann, BC; Rytkin, E; Trampel, KA, 2023) |
| "Dantrolene sodium has been compared with reference antiarrhythmic agents in rodent models of cardiac arrhythmia." | 7.67 | Effects of dantrolene sodium in rodent models of cardiac arrhythmia. ( Brooks, RR; Carpenter, JF; Gregory, CM; Jones, SM, 1989) |
| "The effects of dantrolene sodium on occlusion and reperfusion ventricular arrhythmias (VA) were studied in a canine model." | 7.67 | Effects of dantrolene sodium on occlusion and reperfusion arrhythmias in the canine heart. ( Belhassen, B; Chagnac, A; Laniado, S; Pelleg, A; Roth, A; Shargordsky, B, 1985) |
| "Ryanodine receptor 2 (RyR2) hyperactivity is observed in structural heart diseases that are a result of ischemia or heart failure." | 4.31 | Ryanodine receptor inhibition with acute dantrolene treatment reduces arrhythmia susceptibility in human hearts. ( Brennan-McLean, JA; Efimov, IR; Faye, NR; George, SA; Knollmann, BC; Rytkin, E; Trampel, KA, 2023) |
| "Here, we aimed to investigate whether direct pharmacological intervention in the RV muscle with dantrolene (DAN), a stabilizer of the cardiac ryanodine receptor (RyR2), has a protective effect against RV dysfunction and arrhythmia in a monocrotaline (MCT)-induced PAH rat model." | 4.12 | Stabilization of RyR2 maintains right ventricular function, reduces the development of ventricular arrhythmias, and improves prognosis in pulmonary hypertension. ( Fujii, S; Fukuda, M; Kato, T; Kobayashi, S; Mikawa, M; Nakamura, Y; Nawata, J; Oda, T; Okamura, T; Okuda, S; Suetomi, T; Tanaka, S; Uchinoumi, H; Yamamoto, T; Yano, M, 2022) |
| "Dantrolene sodium has been compared with reference antiarrhythmic agents in rodent models of cardiac arrhythmia." | 3.67 | Effects of dantrolene sodium in rodent models of cardiac arrhythmia. ( Brooks, RR; Carpenter, JF; Gregory, CM; Jones, SM, 1989) |
| "The effects of dantrolene sodium on occlusion and reperfusion ventricular arrhythmias (VA) were studied in a canine model." | 3.67 | Effects of dantrolene sodium on occlusion and reperfusion arrhythmias in the canine heart. ( Belhassen, B; Chagnac, A; Laniado, S; Pelleg, A; Roth, A; Shargordsky, B, 1985) |
| "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a highly malignant inherited arrhythmogenic disorder." | 2.80 | Antiarrhythmic Effects of Dantrolene in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia and Replication of the Responses Using iPSC Models. ( Aalto-Setälä, K; Kontula, K; Lahtinen, AM; Paavola, J; Penttinen, K; Swan, H; Vanninen, S, 2015) |
| "Phenytoin is a hydantoin derivative that is used clinically for the treatment of epilepsy and has been reported to have antiarrhythmic actions on the heart." | 1.56 | Phenytoin Reduces Activity of Cardiac Ryanodine Receptor 2; A Potential Mechanism for Its Cardioprotective Action. ( Ashna, A; Dos Remedios, C; Laver, DR; Molenaar, P; van Helden, DF, 2020) |
| "Dantrolene treatment markedly reduced the rise of [Ca(2+)]i levels caused by chronic administration of ISO (P < ." | 1.42 | Effects of Dantrolene Treatment on Ventricular Electrophysiology and Arrhythmogenesis in Rats With Chronic β-Adrenergic Receptor Activation. ( Huang, CX; Liu, T; Qin, M; Shi, SB, 2015) |
| "The type and mechanisms of these arrhythmias have never been explored and were the aim of the present work." | 1.35 | Increased intracellular Ca2+ and SR Ca2+ load contribute to arrhythmias after acidosis in rat heart. Role of Ca2+/calmodulin-dependent protein kinase II. ( Becerra, R; Copello, JA; Dedman, JR; Diaz-Sylvester, PL; Kaetzel, MA; Mattiazzi, A; Mundiña-Weilenmann, C; Palomeque, J; Rinaldi, G; Said, M; Vittone, L, 2008) |
| "Rhabdomyolysis was suspected." | 1.35 | Rhabdomyolysis after liver transplantation: a case report. ( Chen, CL; Chen, KH; Cheng, KW; Cheng, YF; Chiu, KW; Concejero, AM; Huang, CJ; Huang, TL; Jawan, B; Lin, CC; Liu, YW; Wang, CC; Wang, CS; Wang, SH, 2008) |
| "The patient died on day 3 from cardiocirculatory collapse and arrhythmias." | 1.29 | Hyperthermia complicating tricyclic antidepressant overdose. ( Baud, FJ; Benaissa, M; Clemessy, JL; Hantson, P, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (21.43) | 18.7374 |
| 1990's | 4 (14.29) | 18.2507 |
| 2000's | 3 (10.71) | 29.6817 |
| 2010's | 6 (21.43) | 24.3611 |
| 2020's | 9 (32.14) | 2.80 |
| Authors | Studies |
|---|---|
| Robinson, VM | 1 |
| Alsalahat, I | 1 |
| Freeman, S | 1 |
| Antzelevitch, C | 1 |
| Barajas-Martinez, H | 1 |
| Venetucci, L | 1 |
| Tanaka, S | 2 |
| Yamamoto, T | 3 |
| Mikawa, M | 1 |
| Nawata, J | 2 |
| Fujii, S | 2 |
| Nakamura, Y | 2 |
| Kato, T | 1 |
| Fukuda, M | 1 |
| Suetomi, T | 2 |
| Uchinoumi, H | 2 |
| Oda, T | 2 |
| Okuda, S | 2 |
| Okamura, T | 2 |
| Kobayashi, S | 4 |
| Yano, M | 4 |
| Chang, Y | 1 |
| Yoshitomi, R | 1 |
| Kohno, M | 1 |
| Ishiguchi, H | 1 |
| George, SA | 1 |
| Brennan-McLean, JA | 1 |
| Trampel, KA | 1 |
| Rytkin, E | 1 |
| Faye, NR | 1 |
| Knollmann, BC | 1 |
| Efimov, IR | 1 |
| Wegener, JW | 1 |
| Mitronova, GY | 1 |
| ElShareif, L | 1 |
| Quentin, C | 1 |
| Belov, V | 1 |
| Pochechueva, T | 1 |
| Hasenfuss, G | 1 |
| Ackermann, L | 1 |
| Lehnart, SE | 1 |
| Ashna, A | 1 |
| van Helden, DF | 1 |
| Dos Remedios, C | 1 |
| Molenaar, P | 1 |
| Laver, DR | 2 |
| Yoshiga, Y | 1 |
| Spartalis, M | 1 |
| Iliopoulos, DC | 1 |
| Spartalis, E | 1 |
| Athanasiou, A | 1 |
| Paschou, SA | 1 |
| Voudris, V | 1 |
| Siasos, G | 1 |
| Acsai, K | 1 |
| Nagy, N | 1 |
| Marton, Z | 1 |
| Oravecz, K | 1 |
| Varro, A | 1 |
| Seidel, M | 1 |
| Thomas, NL | 1 |
| Williams, AJ | 1 |
| Lai, FA | 1 |
| Zissimopoulos, S | 1 |
| Liu, T | 1 |
| Shi, SB | 1 |
| Qin, M | 1 |
| Huang, CX | 1 |
| Penttinen, K | 1 |
| Swan, H | 1 |
| Vanninen, S | 1 |
| Paavola, J | 1 |
| Lahtinen, AM | 1 |
| Kontula, K | 1 |
| Aalto-Setälä, K | 1 |
| Walweel, K | 1 |
| Oo, YW | 1 |
| Said, M | 1 |
| Becerra, R | 1 |
| Palomeque, J | 1 |
| Rinaldi, G | 1 |
| Kaetzel, MA | 1 |
| Diaz-Sylvester, PL | 1 |
| Copello, JA | 1 |
| Dedman, JR | 1 |
| Mundiña-Weilenmann, C | 1 |
| Vittone, L | 1 |
| Mattiazzi, A | 1 |
| Huang, CJ | 1 |
| Chen, CL | 1 |
| Wang, CS | 1 |
| Cheng, KW | 1 |
| Chen, KH | 1 |
| Wang, CC | 1 |
| Concejero, AM | 1 |
| Cheng, YF | 1 |
| Huang, TL | 1 |
| Chiu, KW | 1 |
| Wang, SH | 1 |
| Lin, CC | 1 |
| Liu, YW | 1 |
| Jawan, B | 1 |
| Shannon, TR | 1 |
| Lew, WY | 1 |
| Maxwell, JT | 1 |
| Domeier, TL | 1 |
| Blatter, LA | 1 |
| Byrd, JP | 1 |
| Lou, CG | 1 |
| Wingard, DW | 1 |
| Ishide, N | 1 |
| Hantson, P | 1 |
| Benaissa, M | 1 |
| Clemessy, JL | 1 |
| Baud, FJ | 1 |
| Neff, SP | 1 |
| Futter, ME | 1 |
| Anderson, BJ | 1 |
| Pollock, AN | 1 |
| McKenzie, AJ | 1 |
| Hodges, M | 1 |
| Snoeck, MM | 1 |
| Amiel, I | 1 |
| Nivoche, Y | 1 |
| Brooks, RR | 1 |
| Carpenter, JF | 1 |
| Jones, SM | 1 |
| Gregory, CM | 1 |
| Adnet, P | 1 |
| Krivosic-Horber, R | 1 |
| Pelleg, A | 1 |
| Roth, A | 1 |
| Shargordsky, B | 1 |
| Belhassen, B | 1 |
| Chagnac, A | 1 |
| Laniado, S | 1 |
6 reviews available for dantrolene and Arrhythmia
| Article | Year |
|---|---|
Antiarrhythmic potential of drugs targeting the cardiac ryanodine receptor Ca2+ release channel: case study of dantrolene.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Calcium; Dantrolene; Heart; Humans; Myocardiu | 2015 |
The emerging role of calmodulin regulation of RyR2 in controlling heart rhythm, the progression of heart failure and the antiarrhythmic action of dantrolene.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Calmodulin; Dantrolene; Disease Progression; | 2017 |
Malignant hyperthermia.
Topics: Adult; Arrhythmias, Cardiac; Biopsy; Calcium; Child; Child, Preschool; Creatine Kinase; Dantrolene; | 1983 |
Intracellular calcium modulators for cardiac muscle in pathological conditions.
Topics: Animals; Anti-Arrhythmia Agents; Anticonvulsants; Arrhythmias, Cardiac; Benzothiazoles; Caffeine; Ca | 1996 |
[Treatment of malignant hyperthermia crisis during anesthesia].
Topics: Anesthesia, General; Arrhythmias, Cardiac; Dantrolene; Humans; Hyperkalemia; Malignant Hyperthermia; | 1989 |
[Calcium inhibitors and anesthesia].
Topics: Analgesics; Anesthesia, General; Anesthetics; Arrhythmias, Cardiac; Brain Ischemia; Calcium Channel | 1988 |
1 trial available for dantrolene and Arrhythmia
| Article | Year |
|---|---|
Antiarrhythmic Effects of Dantrolene in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia and Replication of the Responses Using iPSC Models.
Topics: Adult; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Calcium; Cell Differentiation; Dantrol | 2015 |
21 other studies available for dantrolene and Arrhythmia
| Article | Year |
|---|---|
A carvedilol analogue, VK-II-86, prevents hypokalaemia-induced ventricular arrhythmia through novel multi-channel effects.
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Calcium; Carvedilol; Dantrolene; Dogs; HEK293 Cell | 2022 |
Stabilization of RyR2 maintains right ventricular function, reduces the development of ventricular arrhythmias, and improves prognosis in pulmonary hypertension.
Topics: Animals; Arrhythmias, Cardiac; Dantrolene; Disease Models, Animal; Hypertension, Pulmonary; Male; Mo | 2022 |
RyR2-targeting therapy prevents left ventricular remodeling and ventricular tachycardia in post-infarction heart failure.
Topics: Animals; Arrhythmias, Cardiac; Calmodulin; Dantrolene; Heart Failure; Mice; Myocardial Infarction; M | 2023 |
RyR2-stabilization therapy with dantrolene against left ventricular remodeling and lethal arrhythmia in heart failure.
Topics: Arrhythmias, Cardiac; Calcium; Dantrolene; Heart Failure; Humans; Ryanodine Receptor Calcium Release | 2023 |
Ryanodine receptor inhibition with acute dantrolene treatment reduces arrhythmia susceptibility in human hearts.
Topics: Action Potentials; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Caffeine; Calcium; Dantrolene; Hear | 2023 |
A dual-targeted drug inhibits cardiac ryanodine receptor Ca
Topics: Animals; Arrhythmias, Cardiac; Biological Transport; Dantrolene; Humans; Mice; Myocytes, Cardiac; Ry | 2024 |
Phenytoin Reduces Activity of Cardiac Ryanodine Receptor 2; A Potential Mechanism for Its Cardioprotective Action.
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Calcium; Calcium Channel Blockers; Cardiotonic Age | 2020 |
Author's reply: The RyR2 - Targeting therapy against lethal arrhythmia.
Topics: Arrhythmias, Cardiac; Dantrolene; Double-Blind Method; Heart Failure; Humans; Morbidity; Ryanodine R | 2020 |
The genesis of ventricular arrhythmias in heart failure patients is based on alterations in cardiac mechanical, morphological, metabolic, electrophysiological properties, and neurohumoral remodeling.
Topics: Arrhythmias, Cardiac; Dantrolene; Double-Blind Method; Heart Failure; Humans; Morbidity | 2020 |
Dantrolene rescues aberrant N-terminus intersubunit interactions in mutant pro-arrhythmic cardiac ryanodine receptors.
Topics: Amino Acid Substitution; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Arrhythmogenic Right Ventricu | 2015 |
Effects of Dantrolene Treatment on Ventricular Electrophysiology and Arrhythmogenesis in Rats With Chronic β-Adrenergic Receptor Activation.
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Calcium; Cardiotonic Agents; Dantrolene; Disease M | 2015 |
Increased intracellular Ca2+ and SR Ca2+ load contribute to arrhythmias after acidosis in rat heart. Role of Ca2+/calmodulin-dependent protein kinase II.
Topics: Acidosis; Action Potentials; Animals; Arrhythmias, Cardiac; Benzylamines; Calcium; Calcium-Binding P | 2008 |
Rhabdomyolysis after liver transplantation: a case report.
Topics: Arrhythmias, Cardiac; Biliary Atresia; Child, Preschool; Dantrolene; Female; Humans; Liver Transplan | 2008 |
Diastolic release of calcium from the sarcoplasmic reticulum: a potential target for treating triggered arrhythmias and heart failure.
Topics: Animals; Arrhythmias, Cardiac; Calcium; Dantrolene; Diastole; Heart Failure; Humans; Membrane Potent | 2009 |
Dantrolene prevents arrhythmogenic Ca2+ release in heart failure.
Topics: Animals; Arrhythmias, Cardiac; Calcium; Cells, Cultured; Dantrolene; Disease Models, Animal; Heart F | 2012 |
Evidence for in vivo biotransformation of nitrous oxide.
Topics: Animals; Arrhythmias, Cardiac; Dantrolene; Heart Arrest; Injections, Intravenous; Swine | 1981 |
Hyperthermia complicating tricyclic antidepressant overdose.
Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Arrhythmias, Cardiac; Body Temperature; Bromocripti | 1996 |
Fatal outcome after propofol sedation in children.
Topics: Acidosis; Arrhythmias, Cardiac; Cardiac Output, Low; Cause of Death; Child; Creatine Kinase; Dantrol | 1997 |
Propofol and malignant hyperthermia susceptibility.
Topics: Acidosis; Adolescent; Adult; Aged; Anesthetics, Intravenous; Arrhythmias, Cardiac; Cause of Death; C | 1997 |
Effects of dantrolene sodium in rodent models of cardiac arrhythmia.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Coronary Vessels; Dantrole | 1989 |
Effects of dantrolene sodium on occlusion and reperfusion arrhythmias in the canine heart.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Pressure; Coronary Disease; Dantrolene; | 1985 |